Free Trial
→ Urgent Buy Alert: My Top Three Quantum Computing Stocks (From Brownstone Research) (Ad)tc pixel Free AMLX Stock Alerts

Amylyx Pharmaceuticals (AMLX) Financials

Amylyx Pharmaceuticals logo
$14.17 -0.14 (-0.98%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$14.24 +0.07 (+0.49%)
As of 10/24/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Amylyx Pharmaceuticals

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -198 49 -302
Consolidated Net Income / (Loss)		 -198 49 -302
Net Income / (Loss) Continuing Operations		 -198 49 -302
Total Pre-Tax Income 		-198 54 -302
Total Operating Income		 -201 39 -315
Total Gross Profit		 19 355 81
Total Revenue		 22 381 87
Operating Revenue		 22 381 87
Total Cost of Revenue		 2.99 25 5.95
Operating Cost of Revenue		 2.99 25 5.95
Total Operating Expenses		 221 317 396
Selling, General & Admin Expense		 127 188 114
Research & Development Expense		 93 128 140
Other Operating Expenses / (Income)		 - 0.00 119
Restructuring Charge		 - 0.00 23
Total Other Income / (Expense), net		 3.74 15 13
Interest & Investment Income		 4.29 16 14
Other Income / (Expense), net		 -0.55 -0.66 -1.21
Income Tax Expense		 0.77 5.03 -0.39
Basic Earnings per Share		 ($3.39) $0.73 ($4.43)
Weighted Average Basic Shares Outstanding		 58.50M 67.23M 68.14M
Diluted Earnings per Share		 ($3.39) $0.70 ($4.43)
Weighted Average Diluted Shares Outstanding		 58.50M 69.99M 68.14M
Weighted Average Basic & Diluted Shares Outstanding		 66.72M 67.78M 88.60M

Quarterly Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -54 -43 1.57 22 21 4.73 -119 -73 -73 -38
Consolidated Net Income / (Loss)		 -54 -43 1.57 22 21 4.73 -119 -73 -73 -38
Net Income / (Loss) Continuing Operations		 -54 -43 1.57 22 21 4.73 -119 -73 -73 -38
Total Pre-Tax Income 		-54 -42 1.40 24 22 6.48 -119 -73 -73 -38
Total Operating Income		 -55 -45 -2.05 20 19 1.93 -122 -76 -76 -41
Total Gross Profit		 0.17 19 66 93 97 99 83 -1.03 0.42 -0.67
Total Revenue		 0.35 22 71 98 103 108 89 -1.02 0.42 -0.67
Operating Revenue		 0.35 22 71 98 103 108 89 -1.02 0.42 -0.67
Total Operating Expenses		 55 64 68 72 79 97 205 75 76 40
Selling, General & Admin Expense		 30 41 44 43 49 52 58 22 18 17
Research & Development Expense		 25 23 24 29 30 45 37 23 57 23
Total Other Income / (Expense), net		 0.80 2.47 3.46 3.81 3.69 4.54 3.58 3.59 2.96 2.47
Interest & Investment Income		 0.60 3.16 3.72 3.89 4.18 4.37 4.33 4.07 3.10 2.32
Other Income / (Expense), net		 0.20 -0.69 -0.26 -0.08 -0.49 0.17 -0.75 -0.48 -0.14 0.16
Income Tax Expense		 -0.13 0.58 -0.17 1.93 1.52 1.75 0.24 0.00 0.00 -0.64
Basic Earnings per Share		 ($0.92) ($0.61) $0.02 $0.33 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54)
Weighted Average Basic Shares Outstanding		 58.53M 58.50M 66.72M 67.23M 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M
Diluted Earnings per Share		 ($0.92) ($0.61) $0.02 $0.31 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54)
Weighted Average Diluted Shares Outstanding		 58.53M 58.50M 70.86M 70.13M 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M
Weighted Average Basic & Diluted Shares Outstanding		 66.26M 66.72M 67.18M 67.38M 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M

Annual Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 13 108 -92
Net Cash From Operating Activities		 -180 12 -168
Net Cash From Continuing Operating Activities		 -180 12 -168
Net Income / (Loss) Continuing Operations		 -198 49 -302
Consolidated Net Income / (Loss)		 -198 49 -302
Depreciation Expense		 0.49 1.09 0.90
Amortization Expense		 -2.06 -9.94 -9.86
Non-Cash Adjustments To Reconcile Net Income		 23 37 189
Changes in Operating Assets and Liabilities, net		 -3.28 -66 -46
Net Cash From Investing Activities		 -239 92 76
Net Cash From Continuing Investing Activities		 -239 92 76
Purchase of Property, Plant & Equipment		 -2.53 -1.24 -0.16
Acquisitions		 - 0.00 -36
Purchase of Investments		 -416 -301 -232
Sale and/or Maturity of Investments		 179 394 344
Net Cash From Financing Activities		 432 3.54 0.35
Net Cash From Continuing Financing Activities		 432 3.54 0.35
Other Financing Activities, net		 231 3.54 0.35
Effect of Exchange Rate Changes		 -0.07 0.16 -0.44
Cash Income Taxes Paid		 0.03 6.39 0.71

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 41 -45 52 133 -113 35 0.35 -96 -2.44 5.56
Net Cash From Operating Activities		 -43 -50 -5.07 8.61 -5.17 14 -0.49 -67 -42 -59
Net Cash From Continuing Operating Activities		 -43 -50 -5.07 8.61 -5.17 14 -0.49 -67 -42 -59
Net Income / (Loss) Continuing Operations		 -54 -43 1.57 22 21 4.73 -119 -73 -73 -38
Consolidated Net Income / (Loss)		 -54 -43 1.57 22 21 4.73 -119 -73 -73 -38
Depreciation Expense		 0.17 0.18 0.20 0.28 0.30 0.30 0.32 0.21 0.22 0.16
Amortization Expense		 -0.09 -1.86 -2.90 -1.98 -2.48 -2.57 -2.58 -3.18 -2.31 -1.79
Non-Cash Adjustments To Reconcile Net Income		 6.14 6.54 7.94 10 11 8.20 121 18 44 5.42
Changes in Operating Assets and Liabilities, net		 4.66 -12 -12 -22 -35 2.89 -0.31 -9.18 -11 -25
Net Cash From Investing Activities		 84 -228 56 123 -108 21 0.82 -29 39 65
Net Cash From Continuing Investing Activities		 84 -228 56 123 -108 21 0.82 -29 39 65
Purchase of Property, Plant & Equipment		 -0.46 -0.62 -0.25 -0.28 -0.36 -0.36 -0.07 -0.09 0.02 -0.02
Sale and/or Maturity of Investments		 85 34 66 124 57 148 74 130 75 65
Net Cash From Financing Activities		 - 232 1.04 1.38 0.89 0.23 0.13 0.03 0.08 0.11
Net Cash From Continuing Financing Activities		 -1.52 232 1.04 1.38 0.89 0.23 0.13 0.03 0.08 0.11
Other Financing Activities, net		 -1.52 232 1.04 1.38 0.89 0.23 0.13 0.03 0.08 0.11
Effect of Exchange Rate Changes		 -0.37 0.51 0.08 -0.02 -0.13 0.24 -0.11 -0.04 0.24 -0.53
Cash Income Taxes Paid		 -0.03 0.05 0.00 -2.56 -2.42 11 -0.28 -0.01 0.02 0.97

Annual Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 391 517 194
Total Current Assets		 382 465 189
Cash & Equivalents		 63 170 77
Short-Term Investments		 284 201 99
Accounts Receivable		 15 40 0.45
Inventories, net		 9.77 38 0.00
Prepaid Expenses		 10 15 12
Plant, Property, & Equipment, net		 2.61 2.69 0.96
Total Noncurrent Assets		 6.71 50 3.24
Other Noncurrent Operating Assets		 6.71 50 3.24
Total Liabilities & Shareholders' Equity		 391 517 194
Total Liabilities		 51 84 29
Total Current Liabilities		 47 82 28
Accounts Payable		 6.26 22 2.94
Accrued Expenses		 38 58 24
Other Current Liabilities		 2.04 2.26 1.52
Total Noncurrent Liabilities		 4.24 1.98 0.46
Noncurrent Deferred Revenue		 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 4.24 1.98 0.46
Commitments & Contingencies		 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 341 433 165
Total Preferred & Common Equity		 341 433 165
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 341 433 165
Common Stock		 695 738 772
Retained Earnings		 -354 -305 -607
Accumulated Other Comprehensive Income / (Loss)		 -0.09 0.20 -0.09

Quarterly Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 181 408 454 467 417 332 251
Total Current Assets		 172 389 427 434 411 327 245
Cash & Equivalents		 108 115 248 135 171 75 72
Short-Term Investments		 55 231 110 220 203 235 163
Accounts Receivable		 0.14 18 33 29 20 4.09 1.73
Inventories, net		 0.56 13 25 32 0.00 0.00 0.00
Prepaid Expenses		 8.34 13 12 17 17 13 9.14
Plant, Property, & Equipment, net		 2.12 2.56 2.64 2.76 2.46 1.47 1.25
Total Noncurrent Assets		 7.13 16 24 30 4.46 3.97 4.20
Other Noncurrent Operating Assets		 7.13 16 24 30 4.46 3.97 4.20
Total Liabilities & Shareholders' Equity		 181 408 454 467 417 332 251
Total Liabilities		 37 55 67 48 93 71 55
Total Current Liabilities		 33 52 64 46 92 70 54
Accounts Payable		 7.05 11 25 6.37 21 4.96 1.49
Accrued Expenses		 24 39 37 37 68 63 50
Other Current Liabilities		 1.99 2.09 2.15 2.20 2.31 2.37 1.97
Total Noncurrent Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60
Other Noncurrent Operating Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 144 353 386 418 324 261 196
Total Preferred & Common Equity		 144 353 386 418 324 261 196
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 144 353 386 418 324 261 196
Common Stock		 456 705 717 728 748 758 765
Retained Earnings		 -312 -353 -331 -310 -424 -496 -569
Accumulated Other Comprehensive Income / (Loss)		 -0.73 0.03 -0.07 -0.15 -0.08 -0.10 0.64

Annual Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 7,700.00% 1,612.94% -77.06%
EBITDA Growth		 -131.75% 114.40% -1,209.24%
EBIT Growth		 -129.51% 118.89% -928.34%
NOPAT Growth		 -143.49% 124.98% -725.70%
Net Income Growth		 -125.60% 124.84% -712.42%
EPS Growth		 74.61% 120.65% -732.86%
Operating Cash Flow Growth		 -140.47% 106.63% -1,506.55%
Free Cash Flow Firm Growth		 0.00% 76.71% -341.31%
Invested Capital Growth		 20.13% 1,079.33% -118.91%
Revenue Q/Q Growth		 6,343.48% 29.42% -55.53%
EBITDA Q/Q Growth		 -6.32% 267.33% -14.83%
EBIT Q/Q Growth		 -5.37% 512.57% -15.59%
NOPAT Q/Q Growth		 -8.80% 1,514.06% -15.65%
Net Income Q/Q Growth		 -7.80% 2,583.61% -16.29%
EPS Q/Q Growth		 51.36% 3,400.00% -15.97%
Operating Cash Flow Q/Q Growth		 -13.54% 123.22% -76.31%
Free Cash Flow Firm Q/Q Growth		 0.00% 60.67% -64.70%
Invested Capital Q/Q Growth		 65.86% -2.03% 69.27%
Profitability Metrics		 - - -
Gross Margin		 86.54% 93.32% 93.19%
EBITDA Margin		 -915.25% 7.69% -371.86%
Operating Margin		 -905.72% 10.19% -360.22%
EBIT Margin		 -908.20% 10.02% -361.61%
Profit (Net Income) Margin		 -892.38% 12.94% -345.36%
Tax Burden Percent		 100.39% 90.74% 99.87%
Interest Burden Percent		 97.87% 142.35% 95.63%
Effective Tax Rate		 0.00% 9.26% 0.00%
Return on Invested Capital (ROIC)		 0.00% 126.36% -875.40%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 122.44% -845.67%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -113.62% 774.52%
Return on Equity (ROE)		 -92.53% 12.73% -100.88%
Cash Return on Invested Capital (CROIC)		 0.00% -53.48% 0.00%
Operating Return on Assets (OROA)		 -81.23% 8.39% -88.86%
Return on Assets (ROA)		 -79.82% 10.84% -84.87%
Return on Common Equity (ROCE)		 -40.88% 12.73% -100.88%
Return on Equity Simple (ROE_SIMPLE)		 -58.24% 11.37% -183.14%
Net Operating Profit after Tax (NOPAT)		 -141 35 -220
NOPAT Margin		 -634.00% 9.25% -252.16%
Net Nonoperating Expense Percent (NNEP)		 -25.93% 3.92% -29.73%
Return On Investment Capital (ROIC_SIMPLE)		 - 8.12% -133.71%
Cost of Revenue to Revenue		 13.46% 6.68% 6.81%
SG&A Expenses to Revenue		 571.88% 49.47% 130.86%
R&D to Revenue		 420.38% 33.66% 160.56%
Operating Expenses to Revenue		 992.25% 83.13% 453.41%
Earnings before Interest and Taxes (EBIT)		 -202 38 -316
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -203 29 -325
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 7.19 2.29 1.57
Price to Tangible Book Value (P/TBV)		 7.19 2.29 1.57
Price to Revenue (P/Rev)		 110.13 2.61 2.97
Price to Earnings (P/E)		 0.00 20.17 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 4.96% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 10.03 0.00
Enterprise Value to Revenue (EV/Rev)		 94.52 1.63 0.95
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 21.25 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 16.32 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 17.68 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 52.23 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.03 -0.93 -0.92
Leverage Ratio		 1.16 1.17 1.19
Compound Leverage Factor		 1.13 1.67 1.14
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 27.01 8.14 -2.94
Noncontrolling Interest Sharing Ratio		 55.82% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 8.20 5.66 6.67
Quick Ratio		 7.77 5.01 6.23
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -143 -33 -147
Operating Cash Flow to CapEx		 -7,120.78% 960.44% -106,781.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.09 0.84 0.25
Accounts Receivable Turnover		 0.00 13.76 4.31
Inventory Turnover		 0.00 1.06 0.00
Fixed Asset Turnover		 14.41 143.77 47.91
Accounts Payable Turnover		 0.56 1.80 0.48
Days Sales Outstanding (DSO)		 0.00 26.53 84.59
Days Inventory Outstanding (DIO)		 0.00 344.99 0.00
Days Payable Outstanding (DPO)		 648.11 203.14 766.42
Cash Conversion Cycle (CCC)		 -648.11 168.38 -681.83
Capital & Investment Metrics		 - - -
Invested Capital		 -6.34 62 -12
Invested Capital Turnover		 -3.12 13.66 3.47
Increase / (Decrease) in Invested Capital		 1.60 68 -74
Enterprise Value (EV)		 2,101 622 83
Market Capitalization		 2,448 994 259
Book Value per Share		 $5.14 $6.42 $2.40
Tangible Book Value per Share		 $5.14 $6.42 $2.40
Total Capital		 341 433 165
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -347 -371 -177
Capital Expenditures (CapEx)		 2.53 1.24 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 11 -15
Debt-free Net Working Capital (DFNWC)		 336 383 161
Net Working Capital (NWC)		 336 383 161
Net Nonoperating Expense (NNE)		 57 -14 81
Net Nonoperating Obligations (NNO)		 -347 -371 -177
Total Depreciation and Amortization (D&A)		 -1.57 -8.85 -8.95
Debt-free, Cash-free Net Working Capital to Revenue		 -51.38% 2.96% -17.71%
Debt-free Net Working Capital to Revenue		 1,509.33% 100.48% 184.30%
Net Working Capital to Revenue		 1,509.33% 100.48% 184.30%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.39) $0.73 ($4.43)
Adjusted Weighted Average Basic Shares Outstanding		 58.50M 67.23M 68.14M
Adjusted Diluted Earnings per Share		 ($3.39) $0.70 ($4.43)
Adjusted Weighted Average Diluted Shares Outstanding		 58.50M 69.99M 68.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.72M 67.78M 88.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -141 35 -204
Normalized NOPAT Margin		 -634.00% 9.25% -233.85%
Pre Tax Income Margin		 -888.89% 14.26% -345.81%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 21.05% 0.00% 0.00% 0.00% 29,666.09% 395.54% 24.10% -101.04% -99.59% -100.61%
EBITDA Growth		 -135.40% -34.66% 89.51% 133.92% 129.50% 99.65% -2,395.89% -532.94% -585.21% -25,278.31%
EBIT Growth		 -135.39% -29.40% 95.16% 137.06% 133.46% 104.65% -5,207.86% -481.56% -515.76% -2,023.85%
NOPAT Growth		 -138.59% -57.49% 93.12% 148.91% 145.59% 104.53% -3,614.16% -387.49% -403.48% -2,114.18%
Net Income Growth		 -132.29% -50.66% 103.29% 140.83% 138.87% 111.08% -7,652.00% -429.35% -447.98% -893.62%
EPS Growth		 73.10% 85.44% 102.15% 133.33% 132.61% 111.48% -8,850.00% -445.16% -456.67% -871.43%
Operating Cash Flow Growth		 -106.46% -75.96% 87.52% 118.53% 88.00% 127.27% 90.36% -873.38% -704.22% -535.45%
Free Cash Flow Firm Growth		 0.00% 0.00% -22.51% -1.33% -227.05% -104.18% -26.03% 199.12% 175.36% 167.69%
Invested Capital Growth		 0.00% 20.13% 148.91% 309.39% 441.26% 1,079.33% -800.56% -266.74% -160.28% -118.91%
Revenue Q/Q Growth		 0.00% 6,243.48% 226.38% 37.50% 4.56% 5.61% -18.26% -101.15% 140.66% -259.86%
EBITDA Q/Q Growth		 -0.20% 13.69% 89.32% 467.33% -12.85% -101.03% -75,287.95% 36.28% 2.32% 45.91%
EBIT Q/Q Growth		 -0.34% 16.89% 94.89% 969.11% -9.38% -88.45% -5,937.39% 37.52% 1.26% 46.58%
NOPAT Q/Q Growth		 -0.79% 18.45% 92.63% 906.97% -6.04% -91.90% -6,150.87% 37.54% 0.82% 46.27%
Net Income Q/Q Growth		 0.58% 20.56% 103.68% 1,303.31% -5.35% -77.36% -2,610.95% 38.80% -0.01% 48.36%
EPS Q/Q Growth		 1.08% 33.70% 103.28% 1,450.00% -3.23% -76.67% -2,600.00% 38.86% 0.00% 49.53%
Operating Cash Flow Q/Q Growth		 7.28% -15.37% 89.79% 269.74% -160.04% 362.16% -103.61% -13,515.54% 37.56% -41.95%
Free Cash Flow Firm Q/Q Growth		 18.16% -66.46% 28.27% -3.70% -164.14% -3.92% 55.73% 181.56% 100.83% -6.66%
Invested Capital Q/Q Growth		 -33.64% 65.86% 210.03% 317.11% 117.80% -2.03% -178.71% 0.72% 21.26% 69.27%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 50.14% 87.11% 92.60% 94.32% 94.92% 91.37% 93.29% 0.00% 100.00% 0.00%
EBITDA Margin		 -15,769.86% -214.58% -7.02% 18.75% 15.63% -0.15% -141.18% 0.00% -18,722.60% 0.00%
Operating Margin		 -15,849.57% -203.76% -2.87% 20.57% 18.23% 1.78% -137.78% 0.00% -18,187.74% 0.00%
EBIT Margin		 -15,791.88% -206.91% -3.24% 20.49% 17.75% 1.94% -138.62% 0.00% -18,221.63% 0.00%
Profit (Net Income) Margin		 -15,581.45% -195.13% 2.20% 22.48% 20.35% 4.36% -134.01% 0.00% -17,476.92% 0.00%
Tax Burden Percent		 99.77% 101.37% 112.12% 91.95% 93.23% 73.05% 100.20% 100.00% 100.00% 98.34%
Interest Burden Percent		 98.90% 93.03% -60.60% 119.32% 122.92% 307.65% 96.48% 94.70% 95.91% 94.28%
Effective Tax Rate		 0.00% 0.00% -12.12% 8.05% 6.77% 26.95% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 477.55% 223.27% 17.80% 0.00% 0.00% -198,826.27% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 476.31% 221.94% 16.88% 0.00% 0.00% -198,819.57% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% -463.81% -204.27% -15.66% 0.00% 0.00% 190,679.53% 0.00%
Return on Equity (ROE)		 -127.76% -92.53% -50.19% 13.74% 19.00% 2.14% -21.00% -51.22% -8,146.74% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,866.06% -342.98% -133.23% -53.48% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -30.03% -18.51% -0.89% 11.58% 16.12% 1.63% -133.68% 0.00% -9,982.69% 0.00%
Return on Assets (ROA)		 -29.63% -17.45% 0.60% 12.71% 18.47% 3.66% -129.24% 0.00% -9,574.70% 0.00%
Return on Common Equity (ROCE)		 -127.76% -40.88% -50.19% 13.74% 19.00% 2.14% -21.00% -51.22% -8,146.74% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -127.76% 0.00% -42.24% -18.85% 0.44% 0.00% -21.91% -63.48% -132.24% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -31 -2.30 19 17 1.41 -85 -53 -53 -28
NOPAT Margin		 -11,094.70% -142.63% -3.22% 18.91% 16.99% 1.30% -96.44% 0.00% -12,731.42% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -19.04% -5.19% 1.29% 1.24% 1.33% 0.92% -9.26% -5.79% -6.70% -3.32%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 0.33% - - - -17.27%
Cost of Revenue to Revenue		 49.86% 12.89% 7.40% 5.68% 5.08% 8.63% 6.71% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 8,678.26% 186.63% 61.61% 44.18% 47.44% 48.17% 65.16% 0.00% 4,285.58% 0.00%
R&D to Revenue		 7,221.45% 104.24% 33.87% 29.57% 29.25% 41.41% 41.30% 0.00% 13,807.69% 0.00%
Operating Expenses to Revenue		 15,899.71% 290.87% 95.48% 73.75% 76.69% 89.59% 231.07% 0.00% 18,287.74% 0.00%
Earnings before Interest and Taxes (EBIT)		 -54 -45 -2.32 20 18 2.11 -123 -77 -76 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -47 -5.01 18 16 -0.17 -125 -80 -78 -42
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 11.44 7.19 5.55 3.75 2.95 2.29 0.59 0.49 1.12 1.57
Price to Tangible Book Value (P/TBV)		 11.44 7.19 5.55 3.75 2.95 2.29 0.59 0.49 1.12 1.57
Price to Revenue (P/Rev)		 4,775.97 110.13 20.90 7.55 4.19 2.61 0.48 0.43 1.12 2.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 671.94 20.17 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.15% 4.96% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 231.11 37.53 13.87 10.03 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 4,304.69 94.52 17.21 5.69 2.99 1.63 0.00 0.00 0.00 0.95
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 21.25 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 16.32 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 17.68 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 52.23 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.03 -1.01 -0.97 -0.92 -0.93 -1.06 -1.03 -0.96 -0.92
Leverage Ratio		 1.26 1.16 1.15 1.17 1.15 1.17 1.22 1.21 1.17 1.19
Compound Leverage Factor		 1.25 1.08 -0.70 1.40 1.42 3.61 1.18 1.15 1.12 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 23.95 28.33 21.23 13.44 16.19 7.91 0.71 0.07 -0.05 1.76
Noncontrolling Interest Sharing Ratio		 0.00% 55.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 5.27 8.20 7.54 6.67 9.52 5.66 4.48 4.66 4.55 6.67
Quick Ratio		 4.98 7.77 7.04 6.10 8.43 5.01 4.30 4.48 4.38 6.23
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -33 -24 -24 -64 -67 -30 24 49 45
Operating Cash Flow to CapEx		 -9,385.19% -8,015.65% -2,028.80% 3,096.76% -1,447.90% 3,806.46% -729.85% -74,808.99% 0.00% -295,040.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.09 0.27 0.57 0.91 0.84 0.96 0.76 0.55 0.25
Accounts Receivable Turnover		 2.52 0.00 0.00 0.00 19.95 13.76 21.00 15.91 12.64 4.31
Inventory Turnover		 0.31 0.00 0.00 0.00 1.15 1.06 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.16 14.41 48.67 85.39 120.61 143.77 158.63 145.38 97.92 47.91
Accounts Payable Turnover		 0.02 0.56 0.80 0.84 2.82 1.80 1.62 1.38 3.90 0.48
Days Sales Outstanding (DSO)		 144.94 0.00 0.00 0.00 18.29 26.53 17.38 22.95 28.87 84.59
Days Inventory Outstanding (DIO)		 1,194.74 0.00 0.00 0.00 318.01 344.99 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 14,965.00 648.11 459.01 432.17 129.60 203.14 225.29 263.56 93.65 766.42
Cash Conversion Cycle (CCC)		 -13,625.32 -648.11 -459.01 -432.17 206.70 168.38 -207.91 -240.61 -64.78 -681.83
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -19 -6.34 6.97 29 63 62 -49 -49 -38 -12
Invested Capital Turnover		 -0.04 -3.12 -25.71 25.25 13.14 13.66 -19.01 -30.78 15.62 3.47
Increase / (Decrease) in Invested Capital		 -19 1.60 21 43 82 68 -56 -78 -102 -74
Enterprise Value (EV)		 1,485 2,101 1,612 1,092 879 622 -182 -181 -14 83
Market Capitalization		 1,648 2,448 1,957 1,449 1,234 994 192 129 221 259
Book Value per Share		 $2.46 $5.14 $5.29 $5.75 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40
Tangible Book Value per Share		 $2.46 $5.14 $5.29 $5.75 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40
Total Capital		 144 341 353 386 418 433 324 261 196 165
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -163 -347 -346 -357 -355 -371 -373 -310 -234 -177
Capital Expenditures (CapEx)		 0.46 0.62 0.25 0.28 0.36 0.36 0.07 0.09 -0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -23 -11 -8.24 6.04 33 11 -54 -53 -43 -15
Debt-free Net Working Capital (DFNWC)		 140 336 337 363 388 383 319 257 191 161
Net Working Capital (NWC)		 140 336 337 363 388 383 319 257 191 161
Net Nonoperating Expense (NNE)		 15 11 -3.87 -3.50 -3.44 -3.32 33 19 20 9.09
Net Nonoperating Obligations (NNO)		 -163 -347 -346 -357 -355 -371 -373 -310 -234 -177
Total Depreciation and Amortization (D&A)		 0.08 -1.68 -2.70 -1.70 -2.18 -2.27 -2.27 -2.97 -2.08 -1.63
Debt-free, Cash-free Net Working Capital to Revenue		 -6,678.55% -51.38% -8.79% 3.15% 11.37% 2.96% -13.67% -17.80% -21.91% -17.71%
Debt-free Net Working Capital to Revenue		 40,449.86% 1,509.33% 360.29% 189.35% 132.04% 100.48% 80.12% 85.90% 97.39% 184.30%
Net Working Capital to Revenue		 40,449.86% 1,509.33% 360.29% 189.35% 132.04% 100.48% 80.12% 85.90% 97.39% 184.30%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.92) ($0.61) $0.02 $0.33 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 58.53M 58.50M 66.72M 67.23M 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M
Adjusted Diluted Earnings per Share		 ($0.92) ($0.61) $0.02 $0.31 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 58.53M 58.50M 70.86M 70.13M 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.26M 66.72M 67.18M 67.38M 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -31 -1.44 19 17 1.41 -85 -37 -53 -28
Normalized NOPAT Margin		 -11,094.70% -142.63% -2.01% 18.91% 16.99% 1.30% -96.44% 0.00% -12,731.42% 0.00%
Pre Tax Income Margin		 -15,617.68% -192.48% 1.96% 24.44% 21.82% 5.97% -133.74% 0.00% -17,476.92% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

The financial data for Amylyx Pharmaceuticals (NASDAQ: AMLX) from Q3 2022 through Q4 2024 reveals several important trends over the last two years. Overall, the company has faced fluctuating revenues, significant net losses in most recent periods, and considerable operating expenses, all typical for a pharmaceutical company investing heavily in research and development.

Positive Highlights:

  • In Q4 2023, AMLX reported a consolidated net income of $4.7 million with a positive operating income of approximately $1.9 million, showing profitability during that quarter compared to losses in later periods.
  • The company consistently generates investment income, ranging from around $3 million to over $4 million per quarter in 2023 and 2024, which partially offsets operating losses.
  • Strong cash and investment positions are apparent, with combined cash & equivalents and short-term investments amounting to over $200 million by early 2024, enabling liquidity for operations and R&D.
  • The gross profit margin was positive and strong in multiple quarters, with total gross profit near $99 million in Q4 2023, indicating good control over direct costs relative to revenue.
  • Non-cash expenses such as depreciation and amortization help reconcile net losses, indicating significant investment in intangible assets and capital expenditures.

Neutral Observations:

  • Operating revenues and total revenues show large variability, with some quarters in 2024 showing negative reported revenues (likely reflecting adjustments or accounting treatments related to contract liabilities or returns).
  • AMLX consistently has high selling, general & administrative (SG&A) and research & development (R&D) expenses, reflecting an ongoing high investment cycle typical for pharma companies developing novel products.
  • Working capital fluctuates due to changes in accrued expenses and accounts payable, implying variable operational cash flow needs.
  • The company has sizable accrued expenses and current liabilities, which investors should monitor for potential impact on liquidity.

Negative Trends:

  • After Q4 2023, the company has returned to significant net losses each quarter in 2024, with Q1 to Q4 losses ranging from about $37 million to $118 million, indicating difficulties in returning to sustained profitability.
  • Operating income is deeply negative in 2024 (e.g., -$40.7 million in Q4 and -$122 million in Q1), driven by very high operating expenses, particularly in R&D and SG&A.
  • Negative total revenues in some 2024 quarters could reflect operational or accounting challenges, potentially impacting investor confidence.
  • The diluted earnings per share have remained negative for 2024 quarters, with a significant deterioration from small positive EPS in 2023 to roughly -$0.54 to -$1.75 in 2024.
  • Net cash from operating activities is consistently negative in 2024 quarters, often exceeding tens of millions in cash burn, raising concerns about the sustainability of current operational funding without further financing.

In summary, Amylyx Pharmaceuticals shows the profile of a clinical-stage biotech company with intermittent profits overshadowed by considerable losses and high cash outflows due to development and administrative expenses. Their strong cash and investment reserves somewhat mitigate short-term liquidity risks. However, the persistent operating losses and negative earnings in 2024 emphasize the need to monitor ongoing cash burn and progress towards revenue generation to achieve profitable scale.

10/26/25 06:23 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

When does Amylyx Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amylyx Pharmaceuticals' net income changed over the last 2 years?

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$301.74 million in 2024, rising from -$198.38 million in 2022. The previous period was $49.27 million in 2023. View Amylyx Pharmaceuticals' forecast to see where analysts expect Amylyx Pharmaceuticals to go next.

What is Amylyx Pharmaceuticals' operating income?
Amylyx Pharmaceuticals' total operating income in 2024 was -$314.73 million, based on the following breakdown:
  • Total Gross Profit: $81.42 million
  • Total Operating Expenses: $396.15 million
How has Amylyx Pharmaceuticals' revenue changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' total revenue changed from $22.23 million in 2022 to $87.37 million in 2024, a change of 293.0%.

How much debt does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals' total liabilities were at $28.87 million at the end of 2024, a 65.6% decrease from 2023, and a 43.2% decrease since 2022.

How much cash does Amylyx Pharmaceuticals have?

In the past 2 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $62.53 million in 2022 to $170.20 million in 2023, and is currently $77.39 million as of their latest financial filing in 2024.

How has Amylyx Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' book value per share changed from 5.14 in 2022 to 2.40 in 2024, a change of -53.2%.


Related Companies

This page (NASDAQ:AMLX) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners
U.S. Government Sparking Crypto Rally
Missed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...
Crypto 101 Media | Sponsoredtc pixel
Elon Musk is on the line
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...
Altimetry | Sponsoredtc pixel
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
Buy the dip? Here’s my #1 gold stock
“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...
Golden Portfolio | Sponsoredtc pixel
The strategy that wins no matter where the market goes
Joel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...
Crypto Swap Profits | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
The End of Elon Musk…?
While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...
Brownstone Research | Sponsoredtc pixel